Search

Glaukos Corp

Closed

SectorHealthcare

237.47 30.54

Overview

Share price change

24h

Current

Min

174.42

Max

186.89

Key metrics

By Trading Economics

Income

1.4M

-18M

Sales

35M

186M

EPS

-0.14

Profit margin

-9.901

Employees

1,094

EBITDA

-333K

-5.6M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+20.89% upside

Market Stats

By TradingEconomics

Market Cap

1.6B

11B

Previous open

206.93

Previous close

237.47

Glaukos Corp Chart

Past performance is not a reliable indicator of future results.

Related News

28 Oct 2026, 23:02 UTC

Social Media
News

Glaukos Corporation reported record Q3 net sales of $211 million and raised its 2026 sales guidance to between $775 million and $785 million.

27 Oct 2026, 20:01 UTC

Glaukos Corporation shares are experiencing higher trading activity today, reaching a notable peak earlier in the session before pulling back slightly.

26 Oct 2026, 23:46 UTC

Glaukos Corp shares are trading higher in after-market hours, remaining near the upper end of their one-month trading range.

22 Oct 2026, 20:07 UTC

Glaukos Corp shares are declining, retracing from an early session peak to approach the day's low amid a slight overall market decline.

21 Oct 2026, 20:07 UTC

Glaukos Corp shares advanced throughout Wednesday, peaking in the afternoon before a slight pullback, remaining above their 20-day moving average.

20 Oct 2026, 20:01 UTC

Glaukos Corp shares are significantly higher, currently 7.32% above their 20-day moving average and near the upper end of their one-month range.

16 Oct 2026, 19:36 UTC

Glaukos Corp shares fell sharply, marking a notable decline since Thursday's close and currently positioned around the midpoint of its one-month trading range.

15 Oct 2026, 20:07 UTC

Glaukos Corp shares are declining, reversing an early spike to finish lower from Wednesday's close amid unusual volatility.

13 Oct 2026, 20:07 UTC

Glaukos Corp shares are declining, following a volatile intraday pattern, closing lower from Monday's close despite briefly recovering earlier in the session.

9 Oct 2026, 20:06 UTC

News
Event

Glaukos reports positive Phase 4 trial results for iDose TR therapy, showing a significant reduction in intraocular pressure alongside cataract surgery, confirming safety.

8 Oct 2026, 22:55 UTC

Glaukos Corp shares declined in after-market hours, continuing a downward trend from Thursday's close and remaining below its 20-day moving average.

7 Oct 2026, 20:00 UTC

Glaukos Corp is advancing significantly with unusually high trading volume, marking a departure from recent higher daily closes since Tuesday.

6 Oct 2026, 20:07 UTC

Glaukos Corp shares are declining, trading below their 20-day moving average and near the lower end of their one-month range after earlier volatility.

1 Oct 2026, 20:07 UTC

Glaukos Corp's shares are declining, positioned near the lower end of their one-month range, after a brief spike earlier in the session.

30 Sept 2026, 20:07 UTC

Glaukos Corp shares are advancing, rebounding from an earlier pullback, amid a broader market trend of significant gains on Wednesday.

29 Sept 2026, 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

28 Sept 2026, 20:07 UTC

Glaukos Corp is gaining ground in today's trading session, reflecting upward momentum since Friday, despite earlier pulling back from a session high.

25 Sept 2026, 20:07 UTC

Glaukos Corp shares fell sharply, closing just below Thursday's close and approximately 9.45% below their 20-day moving average.

23 Sept 2026, 20:01 UTC

News

Glaukos Corporation launched a keratoconus awareness campaign with Stephen Curry, but shares fell sharply today, continuing a trend of three consecutive daily declines.

22 Sept 2026, 23:01 UTC

Glaukos Corp is advancing in after-market trading, reflecting a directional move since Tuesday's close, though it remains 6.99% below its 20-day moving average.

21 Sept 2026, 20:06 UTC

Glaukos Corp's shares are declining, remaining below their 20-day moving average and near the lower end of their one-month range despite an earlier session recovery.

18 Sept 2026, 20:02 UTC

Glaukos Corp is advancing during market hours on Friday, continuing its upward trend since Thursday's close, despite lower trading compared to earlier sessions.

17 Sept 2026, 19:36 UTC

Glaukos Corp shares fell sharply, currently at their lowest point of the day and significantly below the 20-day moving average.

16 Sept 2026, 19:03 UTC

Glaukos Corp shares fell sharply, reversing a trend of higher daily closes, amid unusually high market volume on Wednesday.

14 Sept 2026, 19:16 UTC

Glaukos Corp shares are higher today, despite no specific news, following three consecutive sessions of declines. The stock remains below its 20-day moving average.

11 Sept 2026, 20:08 UTC

Glaukos Corp shares are lower today, continuing a decline over the past four sessions and trading below the 20-day moving average.

10 Sept 2026, 20:03 UTC

Glaukos Corp shares are lower today, breaking a trend of higher closes. The stock is trading with unusually high volume amid no specific news.

8 Sept 2026, 20:07 UTC

Glaukos Corp shares are higher today, recovering from an early dip amid speculation of a potential interest rate hike following a strong jobs report.

1 Sept 2026, 19:31 UTC

Glaukos Corp. shares are lower today amid broader market volatility and rising U.S. Treasury yields, continuing a three-session decline.

31 Aug 2026, 20:07 UTC

Glaukos Corp shares are lower amid broader market concerns over inflation and potential Fed rate hikes. Earlier, the stock rebounded from a session low.

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

20.89% upside

12 Months Forecast

Average 219.333 USD  20.89%

High 251 USD

Low 172 USD

Based on 13 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat